Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Colchicine Debacle Revisited

The Colchicine Debacle Revisited Letters Table 2. Comparison of Trial Characteristics, by Reporting of NNT, NNH, and ARR No. (%) Trials reporting at least 1 Trials not reporting any NNT, NNH, and/or ARR NNT, NNH, and/or ARR Characteristic (n = 292) (n = 583) P value Therapeutic area Cardiology 54 (18.5) 104 (17.8) Diabetes 10 (3.4) 26 (4.5) Infectious disease 43 (14.7) 85 (14.6) <.001 Mood and behavior disorders 20 (6.9) 29 (5.0) Oncology 21 (7.2) 106 (18.2) Other 144 (49.3) 233 (40.0) Type of intervention Drugs, biologics, or vaccines 155 (53.1) 317 (54.4) Surgeries and procedures 42 (14.4) 84 (14.4) Supplements and nutritional interventions 12 (4.1) 37 (6.3) Other 83 (28.4) 145 (24.9) Patient follow-up, median (IQR), mo 12 (3-21) 12 (4-24) .04 Abbreviations: ARR, absolute risk reduction; IQR, interquartile range; Enrollment, median (IQR) 612 (252-1811) 660 (278-2002) .64 NNH, number needed to harm; NNT, Funding number needed to treat. Trials reported were those with at least 1 Any industry 141 (48.3) 282 (48.4) statistically significant (P < .05) Government/nonprofit only 147 (50.3) 287 (49.2) finding for a binary effect or safety Disclosed no funding received or no 4 (1.4) 14 (2.4) outcome or hazard ratio reported in funding statement the abstract. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

The Colchicine Debacle Revisited

JAMA Internal Medicine , Volume 181 (2) – Mar 2, 2021

Loading next page...
 
/lp/american-medical-association/the-colchicine-debacle-revisited-b512Kwr4PA
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/jamainternmed.2020.5044
Publisher site
See Article on Publisher Site

Abstract

Letters Table 2. Comparison of Trial Characteristics, by Reporting of NNT, NNH, and ARR No. (%) Trials reporting at least 1 Trials not reporting any NNT, NNH, and/or ARR NNT, NNH, and/or ARR Characteristic (n = 292) (n = 583) P value Therapeutic area Cardiology 54 (18.5) 104 (17.8) Diabetes 10 (3.4) 26 (4.5) Infectious disease 43 (14.7) 85 (14.6) <.001 Mood and behavior disorders 20 (6.9) 29 (5.0) Oncology 21 (7.2) 106 (18.2) Other 144 (49.3) 233 (40.0) Type of intervention Drugs, biologics, or vaccines 155 (53.1) 317 (54.4) Surgeries and procedures 42 (14.4) 84 (14.4) Supplements and nutritional interventions 12 (4.1) 37 (6.3) Other 83 (28.4) 145 (24.9) Patient follow-up, median (IQR), mo 12 (3-21) 12 (4-24) .04 Abbreviations: ARR, absolute risk reduction; IQR, interquartile range; Enrollment, median (IQR) 612 (252-1811) 660 (278-2002) .64 NNH, number needed to harm; NNT, Funding number needed to treat. Trials reported were those with at least 1 Any industry 141 (48.3) 282 (48.4) statistically significant (P < .05) Government/nonprofit only 147 (50.3) 287 (49.2) finding for a binary effect or safety Disclosed no funding received or no 4 (1.4) 14 (2.4) outcome or hazard ratio reported in funding statement the abstract.

Journal

JAMA Internal MedicineAmerican Medical Association

Published: Mar 2, 2021

References